68ga-phosphonate

Gallium-68 phosphonates are a class of radiopharmaceuticals in which the positron-emitting radionuclide gallium-68 is chelated to a phosphonate or bisphosphonate ligand. These agents are primarily developed for positron emission tomography (PET) imaging of bone metastases and other bone-related pathologies. The mechanism relies on the high affinity of bisphosphonates for hydroxyapatite in bone tissue, allowing targeted imaging of areas with increased bone turnover such as metastatic lesions. One example is [68Ga]Ga-HBED-CC-BP, which demonstrates rapid and stable labeling with gallium-68 and shows excellent uptake in bones during preclinical studies. These compounds offer an alternative to traditional PET tracers like sodium fluoride (Na[18F]F), especially where access to cyclotron-produced isotopes is limited[3][4][6]. Clinical development has included FDA IND approval for human trials as a bone imaging agent[3].

Other names

gallium-68 phosphonategallium68 phosphonategallium 68 phosphonatega-68 phosphonatega68 phosphonatega 68 phosphonate[68ga]ga-bisphosphonate[68ga]ga-hbed-cc-bp